Last update 05 Jun 2025

Carfilzomib

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Carfilzomib (JAN/USAN/INN), NSC-758252, ONO-7057
+ [4]
Action
inhibitors
Mechanism
Proteasome inhibitors
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (20 Jul 2012),
RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Special Review Project (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC40H57N5O7
InChIKeyBLMPQMFVWMYDKT-NZTKNTHTSA-N
CAS Registry868540-17-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
United States
20 Jul 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory Multiple MyelomaPhase 3
United States
08 May 2019
Refractory Multiple MyelomaPhase 3
Japan
08 May 2019
Refractory Multiple MyelomaPhase 3
Austria
08 May 2019
Refractory Multiple MyelomaPhase 3
Bulgaria
08 May 2019
Refractory Multiple MyelomaPhase 3
Czechia
08 May 2019
Refractory Multiple MyelomaPhase 3
Finland
08 May 2019
Refractory Multiple MyelomaPhase 3
France
08 May 2019
Refractory Multiple MyelomaPhase 3
Germany
08 May 2019
Refractory Multiple MyelomaPhase 3
Greece
08 May 2019
Refractory Multiple MyelomaPhase 3
Lithuania
08 May 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Multiple Myeloma
del17p | t(14;16) | t(14;20) ...
1,087
VRd (Bortezomib, Lenalidomide, Dexamethasone)
ezckqekuex(mpxufhuvdl) = fnfjezjjqw nxthfsayxz (ewjxrlobhr )
Positive
30 May 2025
KRd (Carfilzomib, Lenalidomide, Dexamethasone)
ezckqekuex(mpxufhuvdl) = fkrizvwhhs nxthfsayxz (ewjxrlobhr )
Not Applicable
-
djflerdcse(lttzaiomky): aOR = 1.61 (95% CI, 1.48 - 1.77), P-Value = < 0.001
Negative
30 May 2025
No Carfilzomib
Phase 2
Multiple Myeloma
minimal residual disease (MRD) positive
306
DKRd (Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone)
kkqdwlgbdv(vynykobzui): adjusted OR = 2.5 (95% CI, 1.5 - 4.2)
Positive
30 May 2025
KRd (Carfilzomib, Lenalidomide, Dexamethasone)
Phase 2
Multiple Myeloma
HR cytogenetic aberration (CA) (del(17p), t(4;14), t(14;16), ≥3 copies 1q21)
219
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd)
kzdxznqnzs(wzhkwtsyxl) = mOS has not been reached uexesxuiwk (sxehdtakbf )
Positive
30 May 2025
Phase 2
38
tlnrmsypsd(afmajbhaxh) = zsvxeopvro gfkcktzuax (sepaeyzhyb )
Positive
30 May 2025
Phase 3
Multiple Myeloma
Maintenance
81
Carfilzomib, lenalidomide, and dexamethasone (KRd)
vtabrnbhaf(odgdmmilop) = suhcgzdnqj zmofhmicyb (fdkrlipvku )
Positive
30 May 2025
Lenalidomide (R)
vtabrnbhaf(odgdmmilop) = mtjxbkiuis zmofhmicyb (fdkrlipvku )
Phase 2
Multiple Myeloma
next-generation sequencing-based MRD
39
zpoqrormjy(knzzodvese) = zyzuagjumk xhrqaomyjq (jfpkegqtaf, 10^ - 5)
Positive
11 Feb 2025
Phase 1
13
anvdilamic(iwnoobjirj) = ykxuasskap jmfglnobmy (jhwqudlkau )
Positive
20 Jan 2025
Not Applicable
-
MeziVd
redeatthxq(igiikxhdor) = The most common grade 3/4 TEAEs were neutropenia (35.7%), thrombocytopenia (21.4%), and infections (17.9%) with MeziVd; and neutropenia (44.4%) and infections (33.3%) with MeziKd xbsimrxmjr (wtnfruonkc )
-
09 Dec 2024
MeziKd
Phase 2
50
banhgcstog(igwwxmsuhi) = bapqnlcbbl ipuhokoytd (gxjosigufz )
Positive
07 Dec 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free